EA201270149A1 - Ингибиторы bace - Google Patents
Ингибиторы baceInfo
- Publication number
- EA201270149A1 EA201270149A1 EA201270149A EA201270149A EA201270149A1 EA 201270149 A1 EA201270149 A1 EA 201270149A1 EA 201270149 A EA201270149 A EA 201270149A EA 201270149 A EA201270149 A EA 201270149A EA 201270149 A1 EA201270149 A1 EA 201270149A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bace inhibitors
- methods
- inhibitors
- bace
- intermediates
- Prior art date
Links
- 102100021257 Beta-secretase 1 Human genes 0.000 title abstract 2
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
- C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
Согласно настоящему изобретению предложены ингибиторы ВАСЕ формулы Iспособы их применения, промежуточные продукты и способы их получения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22424109P | 2009-07-09 | 2009-07-09 | |
PCT/US2010/041034 WO2011005738A1 (en) | 2009-07-09 | 2010-07-06 | Bace inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201270149A1 true EA201270149A1 (ru) | 2012-06-29 |
EA019892B1 EA019892B1 (ru) | 2014-07-30 |
Family
ID=42985394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201270149A EA019892B1 (ru) | 2009-07-09 | 2010-07-06 | Ингибиторы bace |
Country Status (26)
Country | Link |
---|---|
US (2) | US8278441B2 (ru) |
EP (1) | EP2451793B1 (ru) |
JP (1) | JP5666578B2 (ru) |
KR (1) | KR101362557B1 (ru) |
CN (1) | CN102471296B (ru) |
AR (1) | AR077277A1 (ru) |
AU (1) | AU2010270691B8 (ru) |
BR (1) | BR112012000525A2 (ru) |
CA (1) | CA2764429C (ru) |
CL (1) | CL2012000033A1 (ru) |
CO (1) | CO6480979A2 (ru) |
CR (1) | CR20120011A (ru) |
DO (1) | DOP2012000004A (ru) |
EA (1) | EA019892B1 (ru) |
EC (1) | ECSP12011581A (ru) |
HN (1) | HN2012000012A (ru) |
IL (1) | IL216742A0 (ru) |
MA (1) | MA33492B1 (ru) |
MX (1) | MX2012000510A (ru) |
NZ (1) | NZ596579A (ru) |
PE (1) | PE20120632A1 (ru) |
SG (1) | SG177594A1 (ru) |
TN (1) | TN2011000673A1 (ru) |
TW (1) | TWI405765B (ru) |
WO (1) | WO2011005738A1 (ru) |
ZA (1) | ZA201109385B (ru) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
EP2597087B1 (en) | 2005-10-25 | 2016-03-30 | Shionogi&Co., Ltd. | Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors |
US8168630B2 (en) | 2007-04-24 | 2012-05-01 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
CA2711655C (en) | 2008-01-18 | 2013-03-05 | Eisai R&D Management Co., Ltd. | Condensed aminodihydrothiazine derivative |
KR20130018370A (ko) | 2008-06-13 | 2013-02-20 | 시오노기세야쿠 가부시키가이샤 | β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체 |
WO2010013794A1 (en) * | 2008-07-28 | 2010-02-04 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
MX2011003189A (es) * | 2008-09-30 | 2011-04-27 | Eisai R&D Man Co Ltd | Nuevo derivado de aminodihidrotiazina fusionada. |
CN102186841A (zh) * | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
GB0912777D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydropyrimidone derivatives |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
EP2485590B1 (en) | 2009-10-08 | 2015-01-07 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
US8563543B2 (en) | 2009-10-08 | 2013-10-22 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
AU2010328975B2 (en) | 2009-12-11 | 2015-01-22 | Shionogi & Co. Ltd. | Oxazine derivative |
US20120245155A1 (en) * | 2009-12-11 | 2012-09-27 | Shionogi & Co., Ltd. | Fused heterocyclic compound having amino group |
TWI537263B (zh) | 2010-06-09 | 2016-06-11 | 健生藥品公司 | 使用作為β-分泌酶抑制劑之5,6-二氫-2H-[1,4]-3-基-胺衍生物 |
EP2634186A4 (en) | 2010-10-29 | 2014-03-26 | Shionogi & Co | naphthyridine |
WO2012057247A1 (ja) | 2010-10-29 | 2012-05-03 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
EA022409B1 (ru) | 2010-12-22 | 2015-12-30 | Янссен Фармацевтика Нв | Производные 5,6-дигидроимидазо[1,2-а]пиразин-8-иламина, пригодные в качестве ингибиторов бета-секретазы (васе) |
GB201100181D0 (en) * | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
JP5993875B2 (ja) * | 2011-01-21 | 2016-09-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 縮合アミノジヒドロチアジン誘導体の合成に有用な方法および化合物 |
GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
GB201101140D0 (en) * | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
ES2534973T3 (es) | 2011-03-09 | 2015-04-30 | Janssen Pharmaceutica N.V. | Derivados de 3,4-dihidro-pirrolo[1,2-a]pirazin-1-ilamina útiles como inhibidores de beta-secretasa (BACE) |
WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
US8598161B2 (en) | 2011-05-24 | 2013-12-03 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
US8604024B2 (en) | 2011-05-24 | 2013-12-10 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
US8927535B2 (en) * | 2011-07-06 | 2015-01-06 | Hoffman-La Roche Inc. | Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors |
EP2747769B1 (en) | 2011-08-22 | 2017-08-02 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use |
EP2751116B1 (en) | 2011-08-31 | 2016-10-12 | Pfizer Inc | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
JO3143B1 (ar) | 2012-04-03 | 2017-09-20 | Lilly Co Eli | مركبات تتراهيدرو بيرولو ثيازين |
WO2013162065A1 (en) | 2012-04-27 | 2013-10-31 | Eisai R&D Management Co., Ltd. | Method for producing 5-(difluoromethyl)pyrazine-2-carboxilic acid and production intermediate thereof |
JP6110937B2 (ja) | 2012-05-04 | 2017-04-05 | ファイザー・インク | APP、BACE1、およびBACE2の阻害剤としての複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
GB201212871D0 (en) | 2012-07-20 | 2012-09-05 | Eisai Ltd | Novel compounds |
EP2897964A1 (en) | 2012-09-20 | 2015-07-29 | Pfizer Inc. | Alkyl-substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
WO2014066132A1 (en) * | 2012-10-26 | 2014-05-01 | Eli Lilly And Company | Bace inhibitors |
JP2016502978A (ja) | 2012-12-11 | 2016-02-01 | ファイザー・インク | BACE1の阻害剤としてのヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
EP2935256B1 (en) | 2012-12-19 | 2018-01-24 | Bristol-Myers Squibb Company | 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production |
US9403846B2 (en) | 2012-12-19 | 2016-08-02 | Pfizer Inc. | Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
WO2014120658A1 (en) | 2013-01-29 | 2014-08-07 | Amgen Inc. | Fused multicyclic 3-amino-5,6-dihydro-2h-1,4-thiazine derivatives and their use as beta-secretase inhibitors |
US20140371283A1 (en) | 2013-02-12 | 2014-12-18 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
CA2897678A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
MX366855B (es) * | 2013-03-01 | 2019-07-26 | Amgen Inc | Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso. |
WO2014138484A1 (en) | 2013-03-08 | 2014-09-12 | Amgen Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
JP6387402B2 (ja) | 2013-06-12 | 2018-09-05 | ヤンセン ファーマシューティカ エヌ.ベー. | β−セクレターゼ(BACE)の阻害剤としての4−アミノ−6−フェニル−5,6−ジヒドロイミダゾ[1,5−A]ピラジン−3(2H)−オン誘導体 |
CN105324383B (zh) | 2013-06-12 | 2017-10-31 | 詹森药业有限公司 | 作为β‑分泌酶(BACE)抑制剂的4‑氨基‑6‑苯基‑6,7‑二氢[1,2,3]三唑并[1,5‑A]吡嗪衍生物 |
JO3318B1 (ar) | 2013-06-18 | 2019-03-13 | Lilly Co Eli | مثبطات bace |
WO2015017407A1 (en) | 2013-07-30 | 2015-02-05 | Amgen Inc. | Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta- secretase |
JP6111002B1 (ja) | 2014-04-10 | 2017-04-05 | ファイザー・インク | 2−アミノ−6−メチル−4,4a,5,6−テトラヒドロピラノ[3,4−d][1,3]チアジン−8a(8H)−イル−1,3−チアゾール−4−イルアミド |
US9550762B2 (en) | 2014-08-08 | 2017-01-24 | Amgen, Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
JP2017538753A (ja) | 2014-12-18 | 2017-12-28 | ヤンセン ファーマシューティカ エヌ.ベー. | 2,3,4,5−テトラヒドロピリジン−6−アミンおよび3,4−ジヒドロ−2H−ピロール−5−アミンの化合物のβセクレターゼ阻害剤 |
AR103680A1 (es) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | Inhibidores selectivos de bace1 |
WO2016149057A1 (en) * | 2015-03-19 | 2016-09-22 | Eli Lilly And Company | Selective bace1 inhibitors |
AR104241A1 (es) | 2015-04-29 | 2017-07-05 | Lilly Co Eli | Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos |
US10246429B2 (en) | 2015-08-06 | 2019-04-02 | Amgen Inc. | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
TW201717948A (zh) | 2015-08-10 | 2017-06-01 | H 朗德貝克公司 | 包括給予2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療 |
CN107849056A (zh) * | 2015-08-12 | 2018-03-27 | H.隆德贝克有限公司 | Bace1抑制剂2‑氨基‑7a‑苯基‑3,4,4a,5,7,7a‑六氢呋喃并[3,4‑b]吡啶 |
CN107849011A (zh) | 2015-08-12 | 2018-03-27 | H.隆德贝克有限公司 | 作为bace1抑制剂的2‑氨基‑3‑氟‑3‑(氟甲基)‑6‑甲基‑6‑苯基‑3,4,5,6‑四氢吡啶 |
WO2017051294A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors |
WO2017051303A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
JP2018531923A (ja) * | 2015-09-24 | 2018-11-01 | ファイザー・インク | N−[2−(2−アミノ−6,6−二置換−4,4a,5,6−テトラヒドロピラノ[3,4−d][1,3]チアジン−8a(8H)−イル)−1,3−チアゾール−4−イル]アミド |
TWI675034B (zh) * | 2016-05-20 | 2019-10-21 | 美商美國禮來大藥廠 | 四氫呋喃并<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>化合物及其作為選擇性BACE1抑制劑之用途 |
CA3039586A1 (en) * | 2016-11-04 | 2018-05-11 | Janssen Pharmaceutica Nv | 4,4a,5,7-tetrahydro-3h-furo[3,4-b]pyridinyl compounds |
AU2017376445B2 (en) | 2016-12-15 | 2021-09-30 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
US11021493B2 (en) | 2016-12-15 | 2021-06-01 | Amgen Inc. | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use |
JP7149272B2 (ja) | 2016-12-15 | 2022-10-06 | アムジエン・インコーポレーテツド | β-セクレターゼ阻害剤としてのチアジン誘導体および使用方法 |
WO2018112086A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
MA52722A (fr) | 2016-12-15 | 2021-04-14 | Amgen Inc | Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation |
JP2020509064A (ja) * | 2017-03-07 | 2020-03-26 | ヤンセン ファーマシューティカ エヌ.ベー. | βセクレターゼ阻害剤 |
CA3051764A1 (en) * | 2017-03-07 | 2018-09-13 | Janssen Pharmaceutica Nv | Inhibitors of beta secretase |
KR20190126828A (ko) * | 2017-03-07 | 2019-11-12 | 얀센 파마슈티카 엔.브이. | 베타 세크레타제의 억제제 |
EA201992055A1 (ru) * | 2017-09-07 | 2020-01-30 | Янссен Фармацевтика Нв | Ингибиторы бета-секретазы |
EA201992108A1 (ru) * | 2017-09-07 | 2020-01-27 | Янссен Фармацевтика Нв | Ингибиторы бета-секретазы |
EA201992076A1 (ru) * | 2017-09-07 | 2020-03-19 | Янссен Фармацевтика Нв | Ингибиторы бета-секретазы |
CN110590517A (zh) * | 2019-09-24 | 2019-12-20 | 武汉嘉诺康医药技术有限公司 | 一种3,4-二羟基-2′-氯苯乙酮的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101061113A (zh) * | 2004-11-23 | 2007-10-24 | 默克公司 | 作为β-内分泌抑制剂用于治疗阿耳茨海默氏病的2,3,4,6-四取代吡啶衍生物 |
EP2597087B1 (en) * | 2005-10-25 | 2016-03-30 | Shionogi&Co., Ltd. | Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors |
CN101360722A (zh) * | 2005-11-15 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | 新颖的2-氨基嘧啶衍生物及其用途 |
US8168630B2 (en) | 2007-04-24 | 2012-05-01 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
EP2151435A4 (en) * | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
ITTO20070665A1 (it) * | 2007-09-24 | 2009-03-25 | Rottapharm Spa | Derivati amidinici, tioureici e guanidinici di 2-amminobenzotiazoli e amminobenzotiazine, nuovi agenti farmacologici per il trattamento delle patologie neurodegenerative. |
CA2711655C (en) * | 2008-01-18 | 2013-03-05 | Eisai R&D Management Co., Ltd. | Condensed aminodihydrothiazine derivative |
KR20130018370A (ko) | 2008-06-13 | 2013-02-20 | 시오노기세야쿠 가부시키가이샤 | β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체 |
MX2011003189A (es) * | 2008-09-30 | 2011-04-27 | Eisai R&D Man Co Ltd | Nuevo derivado de aminodihidrotiazina fusionada. |
-
2010
- 2010-06-28 AR ARP100102299A patent/AR077277A1/es not_active Application Discontinuation
- 2010-06-29 TW TW099121275A patent/TWI405765B/zh not_active IP Right Cessation
- 2010-07-06 BR BR112012000525A patent/BR112012000525A2/pt not_active Application Discontinuation
- 2010-07-06 EP EP10731890.9A patent/EP2451793B1/en active Active
- 2010-07-06 MA MA34517A patent/MA33492B1/fr unknown
- 2010-07-06 NZ NZ596579A patent/NZ596579A/en not_active IP Right Cessation
- 2010-07-06 PE PE2012000028A patent/PE20120632A1/es not_active Application Discontinuation
- 2010-07-06 EA EA201270149A patent/EA019892B1/ru not_active IP Right Cessation
- 2010-07-06 KR KR1020127000457A patent/KR101362557B1/ko not_active Expired - Fee Related
- 2010-07-06 CN CN201080030698.1A patent/CN102471296B/zh not_active Expired - Fee Related
- 2010-07-06 SG SG2012001749A patent/SG177594A1/en unknown
- 2010-07-06 AU AU2010270691A patent/AU2010270691B8/en not_active Ceased
- 2010-07-06 CA CA2764429A patent/CA2764429C/en not_active Expired - Fee Related
- 2010-07-06 US US12/830,476 patent/US8278441B2/en not_active Expired - Fee Related
- 2010-07-06 JP JP2012519660A patent/JP5666578B2/ja not_active Expired - Fee Related
- 2010-07-06 WO PCT/US2010/041034 patent/WO2011005738A1/en active Application Filing
- 2010-07-06 MX MX2012000510A patent/MX2012000510A/es active IP Right Grant
-
2011
- 2011-12-01 IL IL216742A patent/IL216742A0/en unknown
- 2011-12-20 ZA ZA2011/09385A patent/ZA201109385B/en unknown
- 2011-12-28 TN TNP2011000673A patent/TN2011000673A1/en unknown
- 2011-12-29 CO CO11181064A patent/CO6480979A2/es active IP Right Grant
-
2012
- 2012-01-04 HN HN2012000012A patent/HN2012000012A/es unknown
- 2012-01-06 DO DO2012000004A patent/DOP2012000004A/es unknown
- 2012-01-06 EC EC2012011581A patent/ECSP12011581A/es unknown
- 2012-01-06 CL CL2012000033A patent/CL2012000033A1/es unknown
- 2012-01-09 CR CR20120011A patent/CR20120011A/es unknown
- 2012-08-16 US US13/587,161 patent/US20120323001A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201270149A1 (ru) | Ингибиторы bace | |
CR11776A (es) | Inhibidores de bace | |
EA201270257A1 (ru) | Производные n1-сульфонил-5-фторпиримидинона | |
EA201490474A1 (ru) | Аминохиназолины в качестве ингибиторов киназ | |
EA201200323A1 (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
EA201490778A1 (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ | |
EA201391540A1 (ru) | Агонисты fgfr1 и способы их применения | |
EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
EA201390929A1 (ru) | Антитела к pcsk9 и способы их применения | |
EA201490567A1 (ru) | Новые бициклические производные дигидрохинолин-2-она | |
EA201190227A1 (ru) | Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
JO3450B1 (ar) | أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز | |
EA201390609A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
EA201290642A1 (ru) | Соединения и способы | |
EA200900441A1 (ru) | Способы и интермедиаты для получения ингибиторов интегразы | |
EA201391274A1 (ru) | Аминохинолины в качестве ингибиторов киназ | |
UA113062C2 (xx) | Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону | |
EA201270590A1 (ru) | Ингибиторы акт | |
EA201490846A1 (ru) | Новые производные арилхинолина | |
EA201590552A1 (ru) | Аминохинолины в качестве ингибиторов киназы | |
EA201301130A1 (ru) | Имидазопиридазины в качестве ингибиторов акт киназы | |
EA201190293A1 (ru) | Пролекарства триптолида | |
EA201270256A1 (ru) | Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |